Divi's Laboratories Q1 Profit Surges 66% on Strong Revenue Growth

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 $DIVISLAB reported a strong first quarter for FY27, with consolidated net profit rising 66% year-on-year to ₹902 crore from ₹545 crore in the corresponding quarter last year. Revenue from operations increased 28% to ₹3,080 crore, driven by healthy demand across its pharmaceutical manufacturing and custom synthesis businesses. The company's total income rose over 24% to ₹3,144 crore, while total expenses increased more than 9% to ₹1,964 crore. Profit before tax (PBT) climbed sharply to ₹1,180 crore from ₹733 crore a year earlier, reflecting improved operating performance. During the quarter, the company also reported a forex loss of ₹7 crore, compared with a forex gain of ₹39 crore in the year-ago period. Additionally, the board approved the appointment of B. Vara Prasad and J. Srinivasa Rao as senior management personnel with effect from August 1, 2026. Industry & Economic Impact: The results highlight continued strength in India's pharmaceutical manufacturing sector, supported by robust demand for active pharmaceutical ingredients (APIs) and custom manufacturing services. Strong revenue and profit growth indicate healthy global demand and improving operational efficiency, reinforcing India's position as a leading pharmaceutical manufacturing hub. From an economic perspective, sustained growth in the pharmaceutical industry supports exports, high-value manufacturing, research and development, and skilled employment. Continued expansion by companies like Divi's Laboratories strengthens India's healthcare supply chain and contributes to long-term industrial and economic growth. Source: Economic Times No Recommendations